Cord blood cells take on stomach cancer: new hope in Late-Stage trial
NCT ID NCT07212933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it can help patients live longer and keep the cancer from growing, while checking for side effects. About 90 adults aged 18 to 70 will take part in this randomized, double-blind trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOLOGICAL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First＆Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can a smart drug home in on Hard-to-Treat cancers?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?